ECT for treatment-resistant schizophrenia: A response from the far east to the UK. NICE report

Journal of ECT

Volumn 22, Issue 1, 2006, Pages 4-12

  Chanpattana, Worrawat ^a   Andrade, Chittaranjan ^b  

^a Bangkok Hospital Medical Center   (Thailand)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Continuation ECT (C ECT); Efficacy; Electroconvulsive therapy (ECT); Maintenance ECT (M ECT); Prediction of response; Schizophrenia; Stimulus dosing; Symptoms responsive to ECT; Thailand; Treatment frequency; Treatment resistance

Indexed keywords

CHLORPROMAZINE; FLUPENTIXOL; NEUROLEPTIC AGENT; TRIHEXYPHENIDYL;

BRAIN DEPTH STIMULATION; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CONVALESCENCE; DAILY LIFE ACTIVITY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG TREATMENT FAILURE; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYNDROME; FACE VALIDITY; HUMAN; MENTAL PATIENT; NARRATIVE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PREDICTION; QUALITY OF LIFE; RELAPSE; REVIEW; SCHIZOPHRENIA; THERAPY EFFECT; TREATMENT DURATION; TREATMENT REFUSAL; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; STANDARD; THAILAND;

ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; ELECTROCONVULSIVE THERAPY; HUMANS; QUALITY OF LIFE; RECURRENCE; SCHIZOPHRENIA; THAILAND;

EID: 33748445506     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/00124509-200603000-00002     Document Type: Review

References (94)

1. Rice DP. Economic burden of mental disorder in the United States. Econ Neurosci. 1999;1:40-44.
2. Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry. 1990;47:761-768.
3. Van Putten T, Marder SR, Mintz J. A controlled-dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry. 1990;47:754-758.
4. McEvoy JP, Hogarty G, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher neuroleptic dose. Arch Gen Psychiatry. 1991;48:739-745.
5. Rifkin A, Doddi S, Karagi B, et al. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry. 1991;48:166-170.
6. Kinon BJ, Kane JM, John C, et al. Treatment of neuroleptic resistant schizophrenia relapse. Psychopharmacol Bull. 1993;29:309-314.
7. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371 -1376.
8. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158:518-526.
9. Pierre JM, Marder SR. Acute efficacy of atypical antipsychotic drugs. In: Csernansky JG, Lauriello J, eds. Atypical Antipsychotics. New York: Marcel Dekker; 2004:151-182.
10. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
11. Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology. 1989;99(suppl):568-572.
12. Kane J. Treatment-resistant schizophrenic patients. J Clin Psychiatry. 1996;57(suppl 9):35-40.
13. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry. 1992;160:46-53.
14. Conley RR, Kelly DL. Long-term efficacy, effectiveness, and safety of atypical antipsychotic drugs. In: Csernansky JG, Lauriello J, eds. Atypical Antipsychotics. New York: Marcel Dekker; 2004:183-217.
15. Cerletti U, Bini L. Un neuvo metodo di shockterapie "L'elettro- shock". Boll Accad Med Roma. 1938;64:136-138.
16. Fink M, Sackeim HA. Convulsive therapy in schizophrenia? Schizophr Bull. 1996;22:7-39.
17. American Psychiatric Association. The Practice of ECT: Recommendations for Treatment, Training and Privileging, 2nd ed. Washington, DC: American Psychiatric Press; 2001.
18. Royal College of Psychiatrists. The ECT Handbook: The Second Report of the Royal College of Psychiatrists' Special Committee on ECT. London: Royal College of Psychiatrists; 1995.
19. American Psychiatric Association. The Practice of ECT: Recommendations for Treatment, Training and Privileging. Washington, DC: American Psychiatric Press; 1990.
20. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Updated Software; 2002.
21. Salzman C. The use of ECT in the treatment of schizophrenia. Am J Psychiatry. 1980;137:1032-1041.
22. Chanpattana W. ECT in schizophrenia. J Psychiatr Assoc Thai. 1999;44:156-170.
23. Andrade C. Electroconvulsive therapy in schizophrenia. In: Mandal MK, Haque-Nizamie S, eds. Schizophrenia. New Delhi: Allied Publishers; 2004:272-303.
24. Sackeim HA. Electroconvulsive therapy for schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia, 2nd ed. Blackwell: Oxford; 2003:517-551.
25. National Institute for Clinical Excellence. Guidance on the Use of Electroconvulsive Therapy. Technology Appraisal 59. London: NICE; 2003.
26. Potter WZ. ECT methodologic issues. Psychopharmacol Bull. 1994;30:455-459.
27. Chanpattana W. Continuation ECT in schizophrenia: a pilot study. J Med Assoc Thai. 1997;80:311-318.
28. Chanpattana W. Maintenance ECT in schizophrenia: a pilot study. J Med Assoc Thai. 1998;81:17-24.
29. Chanpattana W. The use of stabilization period in ECT research in schizophrenia: I. A pilot study. J Med Assoc Thai. 1999;82:1193-1199.
30. Overall JF, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
31. Chanpattana W, Chakrabhand MLS, Kirdcharoen N, et al. The use of the stabilization period in electroconvulsive therapy research in schizophrenia: II. Implementation. J Med Assoc Thai. 1999;82:558-568.
32. Chanpattana W, Chakrabhand MLS, Kongsakon R, et al. Short-term effect of combined ECT and neuroleptic therapy in treatment-resistant schizophrenia. J ECT. 1999;15:129-139.
33. Chanpattana W, Chakrabhand MLS, Sackeim HA, et al. Continuation ECT in treatment-resistant schizophrenia: a controlled study. J ECT. 1999;15:178-192.
34. Chanpattana W, Chakrabhand MLS, Kitaroonchai W, et al. Effects of twice-versus thrice-weekly electroconvulsive therapy in schizophrenia. J Med Assoc Thai. 1999;82:477-483.
35. Chanpattana W. Maintenance ECT in treatment-resistant schizophrenia. J Med Assoc Thai. 2000;83:657-662.
36. Chanpattana W, Chakrabhand MLS. Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: prediction of outcome. Psychiatry Res. 2001;105:107-115.
37. Herzberg F. Prognostic variables for electro-shock therapy. J Gen Psychology. 1954;50:79-86.
38. Wittman P. A scale for measuring prognosis in schizophrenic patients. Elgin Pap. 1941;4:20-33.
39. Kalinowsky LB, Worthing H. Results with electric convulsive therapy in 200 cases of schizophrenia. Psychiatr Q. 1943;17:144-153.
40. Hamilton DM, Wall JH. The hospital treatment of dementia praecox. Am J Psychiatry. 1948;105:346-352.
41. Ellison FA, Hamilton DM. The hospital treatment of dementia praecox: Part II. Am J Psychiatry. 1949;106:454-461.
42. Wells DA. Electroconvulsive treatment for schizophrenia. A ten-year survey in a university hospital psychiatric department. Compr Psychiatry. 1973;14:291-298.
43. Folstein M, Folstein S, McHugh PR. Clinical predictors of improvement after electroconvulsive therapy of patients with schizophrenia, neurotic reactions, and affective disorders. Biol Psychiatry. 1973;7:147-152.
44. Ross JR, Malzberg B. A review of the results of the pharmacological shock therapy and the metrazol convulsive therapy in New York State. Am J Psychiatry. 1939;96:297-316.
45. Kalinowsky LB. Electric convulsion therapy with emphasis on importance of adequate treatment. Arch Neurol Psychiatry. 1943;50:652-660.
46. Cheney CO, Drewry PH. Results of nonspecific treatment in dementia praecox. Am J Psychiatry. 1938;95:203-217.
47. Lowinger L, Huddleson JH. Outcome on dementia praecox under electric shock therapy as related to mode of onset and to number of convulsions induced. J Nerv Ment Dis. 1945;102:243-246.
48. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. BMJ. 1971;iii:599-604.
49. Watt DC, Katz K, Shepherd M. The natural history of schizophrenia: a 5 year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med. 1983;13:663-670.
50. World Health Organization. Schizophrenia: An International Follow-up Study. New York: Wiley; 1979.
51. Koehler K, Sauer H. First rank symptoms as predictors of ECT response in schizophrenia. Br J Psychiatry. 1983;142:280-283.
52. Landmark J, Joseph L, Merskey H. Characteristics of schizophrenic patients and the outcome of fluphenazine and of electroconvulsive treatments. Can J Psychiatry. 1987;32:425-428.
53. Dodwell D, Goldberg D. A study of factors associated with response to electroconvulsive therapy in patients with schizophrenic symptoms. Br J Psychiatry. 1989;154:635-639.
54. Sackeim HA, Decina P, Prohovnik I, et al. Seizure threshold in electroconvulsive therapy. Effects of sex, age, electrode placement, and number of treatments. Arch Gen Psychiatry. 1987;44:355-360.
55. Albus M, Scherer J, Hueber S, et al. The impact of familial loading on gender differences in age at onset of schizophrenia. Acta Psychiatr Scand. 1994;89:132-134.
56. Tamminga CA. Gender and schizophrenia. J Clin Psychiatry. 1997;58(suppl 15):33-37.
57. McGlashan TH, Bardenstein KK. Gender differences in affective, schizoaffective, and schizophrenic disorders. Schizophr Bull. 1990;16:319-329.
58. Torgalsboen AK. Full recovery from schizophrenia: the prognostic role of premorbid adjustment, symptoms at first admission, precipitating events and gender. Psychiatry Res. 1999;88:143-152.
59. Lewine R, Haden C, Caudle J, et al. Sex-onset effects on neuropsychological function in schizophrenia. Schizophr Bull. 1997;23:51-61.
60. Salem JE, Kring AM. The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Clin Psychol Rev. 1998;18:795-819.
61. Scheller-Gilkey G, Lewine RR. Age at onset and sex differences in corpus callosum area in schizophrenia. Schizophr Res. 1999;40:229-235.
62. Szymanski S, Lieberman JA, Alvir JM, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry. 1995;152:698-703.
63. Szymanski S, Lieberman JA, Pollack S, et al. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry. 1996;39:249-254.
64. McGlashan TH. A selective review of recent North American long-term follow up studies of schizophrenia. Schizophr Bull. 1988;14:515-542.
65. Riecher-Rossler A, Hafner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl. 2000;407:58-62.
66. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000;401:3-38.
67. Taylor PJ, Fleminger JJ. ECT for schizophrenia. Lancet. 1980;i:1380-1382.
68. Brandon S, Cowley P, McDonald C, et al. Leicester ECT trial: results in schizophrenia. Br J Psychiatry. 1985;146:177-183.
69. Abraham KR, Kulhara P. The efficacy of electroconvulsive therapy in the treatment of schizophrenia. A comparative study. Br J Psychiatry. 1987;151:152-155.
70. Witton K. Efficacy of ECT following prolonged use of psychotropic drugs. Am J Psychiatry. 1962;119:79.
71. el-Islam MF, Ahmed SA, Erfan ME. The effect of unilateral E.C.T. on schizophrenic delusions and hallucinations. Br J Psychiatry. 1970;117:447-448.
72. Wessels WH. A comparative study of the efficacy of bilateral and unilateral electroconvulsive therapy with thioridazine in acute schizophrenia. S Afr Med J. 1972;46:890-892.
73. Doongaji DR, Jeste DV, Saoji NJ, et al. Unilateral versus bilateral ECT in schizophrenia. Br J Psychiatry. 1973;123:73-79.
74. Bagadia VN, Abhyankar R, Pradhan PV, et al. Reevaluation of ECT in schizophrenia: right temporoparietal versus bitemporal electrode placement. Convuls Ther. 1988;4:215-220.
75. Chanpattana W, Chakrabhand MLS, Buppanharun W, et al. Effects of stimulus intensity on the efficacy of bilateral ECT in schizophrenia: a preliminary study. Biol Psychiatry. 2000;48:222-228.
76. Kongsakon R, Vanichtanom R. Assessment of the differences in MMSE between neurological, psychiatric patients and normal population. J Rajwithi Hosp. 1994;5:99-106.
77. Sackeim HA, Decina P, Prohovnik I, et al. Dosage, seizure threshold, and the antidepressant efficacy of electroconvulsive therapy. Ann N Y Acad Sci. 1986;462:398-410.
78. Sackeim HA, Decina P, Prohovnik I, et al. Seizure threshold in electroconvulsive therapy: effects of sex, age, electrode placement, and number of treatments. Arch Gen Psychiatry. 1987;44:355-360.
79. Sackeim HA, Decina P, Kanzler M, et al. Effects of electrode placement on the efficacy of titrated, low-dose ECT. Am J Psychiatry. 1987;144:1449-1455.
80. Sackeim HA, Decina P, Portnoy S, et al. Studies of dosage, seizure threshold, and seizure duration in ECT. Biol Psychiatry. 1987;22:249-268.
81. Sackeim HA, Devanand DP, Prudic J. Stimulus intensity, seizure threshold, and seizure duration: impact on the efficacy and safety of electroconvulsive therapy. Psychiatr Clin North Am. 1991;14:803-843.
82. Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med. 1993;328:839-846.
83. Lerer B, Shapira B, Calev A, et al. Antidepressant and cognitive effects of twice-versus three-times-weekly ECT. Am J Psychiatry. 1995;152:564-570.
84. Shapira B, Tubi N, Drexler H, et al. Cost and benefit in the choice of ECT schedule. Twice versus three times weekly ECT. Br J Psychiatry. 1998;172:44-48.
85. Andrade C, Kurinji S. Continuation and maintenance ECT: a review of recent research. J ECT. 2002;18:149-158.
86. Braga RJ, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J ECT. 2005;21:75-83.
87. Moore MP. The maintenance treatment of chronic psychotics by electrically induced convulsions. J Ment Sci. 1943;89:257-269.
88. Kramer BA. Maintenance ECT: a survey of practice. Convuls Ther. 1987;3:260-268.
89. Petrides G. Continuation ECT: a review. Psychiatr Ann. 1998;28:517-523.
90. Chanpattana W, Chakrabhand MLS. Factors influencing treatment frequency of continuation ECT in schizophrenia. J ECT. 2001;17:190-194.
91. McCall WV, Dunn A, Rosenquist PB. Quality of life and function after electroconvulsive therapy. Br J Psychiatry. 2004;185:405-409.
92. Chanpattana W, Kramer BA. Acute and maintenance ECT with flupentixol in refractory schizophrenia: sustained improvements in psychopathology, quality of life, and social outcomes. Schizophr Res. 2003;63:189-193.
93. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-397.
94. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry. 1992;149:1148-1156.